Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study

Basit Öğe Kaydı
dc.authoridTaskapan, Mehmet Cagatay/0000-0002-5273-4909
dc.authoridSahin, Ibrahim/0000-0002-6231-0034
dc.authorwosidKarakurt, Feridun/KHY-4589-2024
dc.authorwosidTaskapan, Mehmet Cagatay/ABI-7747-2020
dc.authorwosidŞahin, İbrahim/HHY-8303-2022
dc.authorwosidSerter, Rüştü/W-8968-2018
dc.authorwosidSahin, Ibrahim/ABI-6050-2020
dc.contributor.authorSahin, I
dc.contributor.authorSerter, R
dc.contributor.authorKarakurt, F
dc.contributor.authorDemirbas, B
dc.contributor.authorCulha, C
dc.contributor.authorTaskapan, C
dc.contributor.authorKosar, F
dc.date.accessioned2024-08-04T20:35:41Z
dc.date.available2024-08-04T20:35:41Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn addition to the reproductive consequences, polycystic ovary syndrome (PCOS) is characterized by a metabolic disorder in which hyperinsulinemia and insulin resistance are central features. The effects and possible benefits from insulin-sensitizing, drugs are not well known, especially in non-obese women with PCOS. This study was designed to evaluate the effects of metformin and flutamide on metabolic parameters and insulin resistance in non-obese women with PCOS. Thirty non-obese women newly diagnosed with PCOS and 15 age- and weight-matched healthy volunteers as controls were included in the study. Patients were assigned randomly to receive flutamide 250 mg daily or metformin 850 mg three times daily. Glucose, insulin, insulin resistance, androgen levels and glucose and insulin responses to an oral glucose tolerance tests (OGTT) were assessed before and after a 4-week therapy period. A positive correlation was found between body mass index and insulin level in patients with PCOS and controls. Follicle stimulating hormone.en_US
dc.identifier.doi10.1080/09513590400004736
dc.identifier.endpage124en_US
dc.identifier.issn0951-3590
dc.identifier.issn1473-0766
dc.identifier.issue3en_US
dc.identifier.pmid15697072en_US
dc.identifier.scopus2-s2.0-8444244087en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage115en_US
dc.identifier.urihttps://doi.org/10.1080/09513590400004736
dc.identifier.urihttps://hdl.handle.net/11616/95518
dc.identifier.volume19en_US
dc.identifier.wosWOS:000225106300001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofGynecological Endocrinologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPCOSen_US
dc.subjectinsulin sensitivityen_US
dc.subjectandrogensen_US
dc.subjectmetforminen_US
dc.subjectflutamideen_US
dc.titleMetformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu